Evidence map›Paper›PMID 30880941›Full record

ArticleInternational journal of chronic obstructive pulmonary disease

Improving usability and maintaining performance: human-factor and aerosol-performance studies evaluating the new reusable Respimat inhaler.

Rajiv Dhand, Joachim Eicher, Michaela Hänsel, Ingeborg Jost, Martin Meisenheimer, Herbert Wachtel

Open access · goldAbstract readMulticenter StudyVideo-Audio Media
In one paragraph

Article in International journal of chronic obstructive pulmonary disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 27 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. [Inhaled Respiratory Therapy and Global Warming].Farmaceuticos comunitarios · 2025
    Observational
  5. Review
  6. Article
  7. Clinical Implications of Peak Inspiratory Flow in COPD: Post Hoc Analyses of the TRONARTO Study.International journal of chronic obstructive pulmonary disease · 2023
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Rajiv DhandDepartment of Medicine, University of Tennessee Graduate School of Medicine, Knoxville, TN 37920, USA.
Joachim EicherBoehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein 55216, Germany, herbert.wachtel@boehringer-ingelheim.com.
Michaela HänselBoehringer Ingelheim International GmbH, Ingelheim am Rhein 55216, Germany.
Ingeborg JostBoehringer Ingelheim Pharma, Biberach an der Riss 88397, Germany.
Martin MeisenheimerBoehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein 55216, Germany, herbert.wachtel@boehringer-ingelheim.com.
Herbert WachtelBoehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein 55216, Germany, herbert.wachtel@boehringer-ingelheim.com.
Boehringer Ingelheim (Germany) · DEBoehringer Ingelheim (China) · CNUniversity of Tennessee at Knoxville · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe Respimat is a handheld, propellant-free, soft-mist inhaler. Observations by patients and physicians prompted development of an improved second-generation Respimat inhaler. Human-factor studies assessing the usability of the new inhaler and in vitro assessment of aerosol performance are important to demonstrate functionality of the updated inhaler.

methodsStudies were performed to assess any possible impact of the reusable Respimat inhaler design on aerosol performance (delivered dose [DD] and fine-particle dose [FPD]) and iteratively assess and improve usability of the new design. The tiotropium-olodaterol inhalation solution for Respimat was used as a model. The DD and FPD of the reusable Respimat inhaler (across multiple cartridges) and the disposable Respimat inhaler were determined by laser diffraction and with an alternative Andersen cascade impactor. Usability was measured across three studies involving health care professionals and patients with diagnoses of COPD, asthma, or combined disease (with and without experience with the Respimat inhaler). These studies measured performance of handling tasks and collected subjective feedback directly related to the inhaler's new or altered features, which fed into optimization of the inhaler.

resultsDDs of tiotropium and olodaterol were stable up to 15 cartridges and consistently within the upper and lower limits of the disposable Respimat inhaler. The FPD was also found to be batch-consistent over the cartridges and comparable with the reference. The usability of the reusable Respimat inhaler compared with the disposable inhaler was improved in terms of assembly and daily use. Cartridge exchange was rated as intuitive and easy to very easy.

conclusionThe new reusable Respimat is a medical inhaler developed with enhanced features that meets health care professionals' and patients' needs. Drug delivery across multiple cartridges is not affected by the design. Compared with the original disposable inhaler, the usability of the reusable inhaler has been improved, and cartridge exchange was rated as easy to perform. The reusable Respimat provides greater convenience for patients vs the disposable inhaler, with reduced environmental impact.

Indexed as

Nebulizers and VaporizersPatient Education as TopicAdministration, InhalationAdolescentAdrenergic beta-2 Receptor AgonistsAdultAerosolsAgedAlbuterol, Ipratropium Drug CombinationBrazilChildCholinergic AntagonistsEquipment DesignEuropeFeedbackFemaleAdrenergic beta-2 Receptor AgonistsAerosolsAlbuterol, Ipratropium Drug CombinationCholinergic AntagonistsenvironmenthandlinginhalersSMIsoft mist

Identifiers

PMID30880941
PMCPMC6407979
OpenAlexW2919222763

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.